Thu, Jun 27, 9:14 PM (72 days ago)
Aethlon Medical, Inc.'s Form 10-K for the fiscal year ended March 31, 2024, highlights several key aspects of its financial performance and strategic direction. The company, focused on developing the Hemopurifier device for cancer and viral infections, reported no revenue for FY2024, down from $574,245 in FY2023. Research and development costs were approximately $2.52 million, slightly lower than the previous year's $2.75 million. The company has over $9.1 million in cash but acknowledges substantial doubt about its ability to sustain operations for the next 12 months without additional financing. Strategically, Aethlon is advancing its Hemopurifier through clinical trials in the U.S., Australia, and India, targeting oncology and viral infections, including COVID-19. The FDA has designated the Hemopurifier as a "Breakthrough Device" for specific cancer and viral infection treatments. However, the company faces significant risks, including dependency on third-party suppliers, regulatory hurdles, and intense competition. Future outlook hinges on successful clinical trials, regulatory approvals, and securing additional funding.